Inactief instrument

Andere talen Interpace Biosciences, Inc. Other OTC

Aandelen

IDXG

US46062X3035

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Interpace Biosciences Announces First Quarter 2024 Financial and Business Results	09/05
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M	07/03
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results	07/03
Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Interpace Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Robert Gorman Provides Notice to Interpace Biosciences, Inc. of His Resignation as A Director and as Chairman of the Board, Including as A Member of the Board?s Regulatory Compliance Committee	12/12
Interpace Biosciences, Inc. Announces Resignation of Edward Chan as Class II Director	16/11
Interpace Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08/11
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results	08/11
Interpace Biosciences, Inc. Enters Amendment to Loan Security Agreement with Broadoak Fund V, L.P	27-10-23
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results	09-08-23
Interpace Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09-08-23
Interpace Biosciences, Inc. Appoints Christopher Mccarthy as Chief Financial Officer	02-08-23
Interpace Biosciences Releases Preliminary Record Second Quarter 2023 Business Results; Updates Status of PancraGEN® Reimbursement	10-07-23
Interpace Expects to Stop Offering PancraGEN® Test Due to CMS Decision to End Reimbursement as of July 17, 2023	05-06-23
Interpace Biosciences, Inc. Expects to Stop Offering Pancragen Test Due to CMS Decision to End Reimbursement as of July 17, 2023	05-06-23
Interpace Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12-05-23
Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q1 Revenue $9.8M	12-05-23
Interpace Biosciences Announces Record First Quarter 2023 Financial and Business Results	12-05-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Interpace Biosciences, Inc. Other OTC

Aandelen

IDXG

US46062X3035

Andere talen

Filters